Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Frontline BR Plus ASCT and Maintenance Rituximab Demonstrates Activity in Transplant-Eligible MCL

October 10th 2022

Bendamustine plus rituximab followed by autologous stem cell transplant and maintenance rituximab led to comparable outcomes defined by progression-free survival and objective response rate compared with R-CHOP/R-DHAP and ASCT as induction therapy in patients with mantle cell lymphoma.

Dr. Danilov on the Differences Between Covalent and Noncovalent BTK Inhibitors in MCL

October 7th 2022

Alexey V. Danilov, MD, PhD, discusses the key differences between covalent and noncovalent BTK inhibitors in mantle cell lymphoma.

Rituximab Maintenance Following First-line BR/R-CHOP Offers Significant Real-World Benefits in MCL

September 23rd 2022

Maintenance treatment with rituximab following first-line treatment with rituximab plus bendamustine or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone produced an overall survival benefit in older patients with mantle cell lymphoma.

NVG-111 Generates Early Efficacy With Manageable Safety in Relapsed/Refractory CLL, MCL

September 14th 2022

The ROR1-targeting bispecific T-cell engager NVG-111 elicited promising responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Brexu-cel Elicits Sustained 3-Year Responses in Relapsed/Refractory MCL

September 14th 2022

Treatment with brexucabtagene autoleucel drove durable responses in patients with relapsed/refractory mantle cell lymphoma, particularly those with minimal residual disease negativity at 6 months.

Late Effects Arise Irrespective of High-Dose Chemotherapy and ASCT Status in MCL

September 13th 2022

Intensive first-line treatment with high-dose chemotherapy and autologous stem cell transplant was not associated with higher rates of late effects compared with outcomes from less intensive therapies in patients with mantle cell lymphoma.

Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL

September 9th 2022

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL

August 17th 2022

Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.

New Acalabrutinib Tablet Formulation Approved for Current Indications, Including CLL, SLL, and MCL

August 5th 2022

The FDA has approved a new tablet formulation of acalabrutinib for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and for those with relapsed or refractory mantle cell lymphoma.

Dr. Kahl on the Current Unmet Needs in MCL

July 26th 2022

Brad S. Kahl, MD, discusses unmet needs in mantle cell lymphoma.

Zilovertamab/Ibrutinib Combo Under Exploration to Fill Unmet Need in Relapsed/Refractory MCL

July 26th 2022

The addition of zilovertamab to ibrutinib will be compared with ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma as part of the phase 3 ZILO-301 trial.

P53-Mutated MCL Remains Difficult to Treat

July 22nd 2022

Mutations in the p53 gene are associated with poor prognosis for patients with mantle cell lymphoma. Although modern regimens have improved outcomes, those treatments are associated with significant toxicity and, so far, have produced limited efficacy.

Zanubrutinib Displays Improved Efficacy Vs Orelabrutinib in Relapsed/Refractory CLL/SLL and MCL

July 22nd 2022

Zanubrutinib demonstrated a significant improvement in progression-free survival compared with orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma or mantle cell lymphoma.

Increased Treatment Efficacy in p53-Mutated MCL Remains Elusive

July 21st 2022

Tycel Jovelle Phillips, MD, outlines the reasons why p53-mutated mantle cell lymphoma is difficult to treat and discusses potential future directions for the treatment of this subgroup of patients.

Dr. Phillips on p53 Mutations in MCL

July 20th 2022

Tycel Jovelle Phillips, MD, discusses the role of p53 mutations in the outcomes of patients with mantle cell lymphoma.

Dr. Kahl on the Evolving Standard of Care in MCL

July 20th 2022

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL

July 20th 2022

Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.

Ibrutinib Plus Bendamustine and Rituximab Prolongs PFS Benefit in Newly Diagnosed MCL

June 21st 2022

Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.

Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCL

June 10th 2022

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.

Pirtobrutinib Under Exploration in Patients with Previously Treated MCL

June 10th 2022

Single-agent pirtobrutinib is being investigated for safety and efficacy in heavily pretreated, BTK inhibitor–naïve patients with mantle cell lymphoma in the ongoing phase 3 BRUIN-MCL-321 trial.